Company Profile
Rezolute Stock Price, News & Catalysts
- Ticker:
- RZLT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.01 USD (-1.57%)
Close
Last updated: August 24, 2026
385M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, RZLT closed down 1.57% at $5.01. No new same-company headline was identified in the current news window.
Company overview
Business overview
Rezolute is a rare-disease and endocrine company focused on hypoglycemia and metabolic disorders. Its programs target difficult hormonal diseases with few effective therapies.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Rezolute sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical data, dose strategy, and the chance to build value in rare endocrine disease.
Position Within the Biotechnology Landscape
Rezolute is a small-cap rare-disease catalyst name whose valuation depends on proof-of-concept and execution.
Future catalysts
- Rezolute’s catalyst is ersodetug in hyperinsulinism, where each clinical and regulatory step can materially change the valuation. The market will care about whether the program keeps moving toward a real rare-disease opportunity.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rezolute (RZLT)?
Rezolute (RZLT) most recently closed at 5.01 USD, a -1.57% move versus the previous session.
What is the market cap of Rezolute (RZLT)?
Rezolute currently has a market capitalization of 385M USD on BioPharmSignal.
What does Rezolute do?
Rezolute is a rare-disease and endocrine company focused on hypoglycemia and metabolic disorders. Its programs target difficult hormonal diseases with few effective therapies.
On which exchange is RZLT stock listed?
Rezolute (RZLT) is associated with NASDAQ, United States, Biopharma.
What is Rezolute?
Rezolute’s catalyst is ersodetug in hyperinsulinism, where each clinical and regulatory step can materially change the valuation.
Which conditions is Rezolute targeting with Rezolute?
Rezolute is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Rezolute describe recent progress with Rezolute?
Rezolute’s catalyst is ersodetug in hyperinsulinism, where each clinical and regulatory step can materially change the valuation.
What future catalysts are investors watching for Rezolute?
Rezolute’s catalyst is ersodetug in hyperinsulinism, where each clinical and regulatory step can materially change the valuation. The market will care about whether the program keeps moving toward a real rare-disease opportunity.